Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

HYPerspectral Enhanced Reality (HYPER): a physiology-based surgical guidance tool.

Barberio M, Longo F, Fiorillo C, Seeliger B, Mascagni P, Agnus V, Lindner V, Geny B, Charles AL, Gockel I, Worreth M, Saadi A, Marescaux J, Diana M.

Surg Endosc. 2019 Jul 15. doi: 10.1007/s00464-019-06959-9. [Epub ahead of print]

PMID:
31309313
2.

Short-term outcomes of laparoscopic repeat liver resection after open liver resection: a systematic review.

Wakabayashi T, Felli E, Memeo R, Mascagni P, Abe Y, Kitagawa Y, Pessaux P.

Surg Endosc. 2019 Jul;33(7):2083-2092. doi: 10.1007/s00464-019-06754-6. Epub 2019 Mar 18.

PMID:
30887184
3.

Colocutaneous fistula through ulcerative colitis and cancer to the pyoderma gangrenosum: a never-ending story for a single patient. Case report.

Eberspacher C, Mascagni D, Fralleone L, Maturo A, Di Matteo FM, De Cristofaro F, Merletti D, Santoro A, Mascagni P, Pontone S, Pironi D.

G Chir. 2019 Jan-Feb;40(1):39-43.

PMID:
30771797
4.

Democratizing Endoscopic Submucosal Dissection: Single-Operator Fully Robotic Colorectal Endoscopic Submucosal Dissection in a Pig Model.

Mascagni P, Lim SG, Fiorillo C, Zanne P, Nageotte F, Zorn L, Perretta S, de Mathelin M, Marescaux J, Dallemagne B.

Gastroenterology. 2019 May;156(6):1569-1571.e2. doi: 10.1053/j.gastro.2018.12.046. Epub 2019 Feb 12. No abstract available.

PMID:
30768985
5.

Aberrant splenic artery rising from the superior mesenteric artery: a rare but important anatomical variation.

Felli E, Wakabayashi T, Mascagni P, Cherkaoui Z, Faucher V, Pessaux P.

Surg Radiol Anat. 2019 Mar;41(3):339-341. doi: 10.1007/s00276-018-02177-5. Epub 2019 Jan 3.

PMID:
30607500
6.

Adaptation of the fundamentals of laparoscopic surgery box for endoscopic simulation: performance evaluation of the first 100 participants.

Habaz I, Perretta S, Okrainec A, Crespin OM, Kwong AV, Weiss E, van der Velden E, Guerriero L, Longo F, Mascagni P, Liu LWC, Jackson TD, Swanstrom LL, Shlomovitz E.

Surg Endosc. 2019 Jan 2. doi: 10.1007/s00464-018-06617-6. [Epub ahead of print]

PMID:
30604259
7.

Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.

Marampon F, Leoni F, Mancini A, Pietrantoni I, Codenotti S, Letizia F, Megiorni F, Porro G, Galbiati E, Pozzi P, Mascagni P, Budillon A, Maggio R, Tombolini V, Fanzani A, Gravina GL, Festuccia C.

J Cancer Res Clin Oncol. 2019 Feb;145(2):393-409. doi: 10.1007/s00432-018-2800-8. Epub 2018 Nov 24.

PMID:
30474756
8.

Feasibility and Value of the Critical View of Safety in Difficult Cholecystectomies.

Felli E, Mascagni P, Wakabayashi T, Mutter D, Marescaux J, Pessaux P.

Ann Surg. 2019 Apr;269(4):e41. doi: 10.1097/SLA.0000000000003096. No abstract available.

PMID:
30418205
9.

Level- and sport-specific Star Excursion Balance Test performance in female volleyball players.

Vitale JA, Vitale ND, Cavaleri L, Dazzan E, Lombardi G, Mascagni P, La Torre A, Banfi G.

J Sports Med Phys Fitness. 2019 May;59(5):733-742. doi: 10.23736/S0022-4707.18.08691-7. Epub 2018 Oct 10.

PMID:
30317834
10.

New intraoperative imaging technologies: Innovating the surgeon's eye toward surgical precision.

Mascagni P, Longo F, Barberio M, Seeliger B, Agnus V, Saccomandi P, Hostettler A, Marescaux J, Diana M.

J Surg Oncol. 2018 Aug;118(2):265-282. doi: 10.1002/jso.25148. Epub 2018 Aug 4. Review.

PMID:
30076724
11.

Control of cytokine mRNA degradation by the histone deacetylase inhibitor ITF2357 in rheumatoid arthritis fibroblast-like synoviocytes: beyond transcriptional regulation.

Angiolilli C, Kabala PA, Grabiec AM, Rossato M, Lai WS, Fossati G, Mascagni P, Steinkühler C, Blackshear PJ, Reedquist KA, Baeten DL, Radstake TRDJ.

Arthritis Res Ther. 2018 Jul 20;20(1):148. doi: 10.1186/s13075-018-1638-4.

12.

Pilonidal disease mimicking anterior anal fistula and associated with posterior anal fistula: a two-step surgery. Case report.

Eberspacher C, Mascagni D, Fralleone L, Grimaldi G, Antypas P, Mascagni P, Maturo A, Di Matteo FM, Pontone S, Pironi D.

G Chir. 2017 Nov-Dec;38(6):313-317.

13.

Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism.

Jeong MY, Lin YH, Wennersten SA, Demos-Davies KM, Cavasin MA, Mahaffey JH, Monzani V, Saripalli C, Mascagni P, Reece TB, Ambardekar AV, Granzier HL, Dinarello CA, McKinsey TA.

Sci Transl Med. 2018 Feb 7;10(427). pii: eaao0144. doi: 10.1126/scitranslmed.aao0144.

14.

Spontaneous hepatic rupture in a bodybuilder: a case report and review of the literature.

Mascagni P, Melandro F, Larghi Laureiro Z, Mennini G, Rossi M.

Rev Esp Enferm Dig. 2018 Apr;110(4):254-256. doi: 10.17235/reed.2017.5103/2017.

15.

Muzi's Tension Free Primary Closure of Pilonidal Sinus Disease: Updates on Long-Term Results on 514 Patients.

Muzi MG, Mascagni P, Buonomo O, Cianfarani A, Mosconi C, Colella M, Balla A, Petrella G, Quaresima S, Sileri P.

J Gastrointest Surg. 2018 Jan;22(1):133-137. doi: 10.1007/s11605-017-3502-2. Epub 2017 Jul 27.

PMID:
28752401
16.

Allergic Contact Dermatitis Caused by Argan Oil.

Veraldi S, Mascagni P, Tosi D, Brena M.

Dermatitis. 2016 Nov/Dec;27(6):391. No abstract available.

PMID:
27775969
17.

Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes.

Angiolilli C, Kabala PA, Grabiec AM, Van Baarsen IM, Ferguson BS, García S, Malvar Fernandez B, McKinsey TA, Tak PP, Fossati G, Mascagni P, Baeten DL, Reedquist KA.

Ann Rheum Dis. 2017 Jan;76(1):277-285. doi: 10.1136/annrheumdis-2015-209064. Epub 2016 Jul 25.

18.

Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo.

Li S, Fossati G, Marchetti C, Modena D, Pozzi P, Reznikov LL, Moras ML, Azam T, Abbate A, Mascagni P, Dinarello CA.

J Biol Chem. 2015 Jan 23;290(4):2368-78. doi: 10.1074/jbc.M114.618454. Epub 2014 Dec 1.

19.

Histone deacetylase inhibitors modulate interleukin 6-dependent CD4+ T cell polarization in vitro and in vivo.

Glauben R, Sonnenberg E, Wetzel M, Mascagni P, Siegmund B.

J Biol Chem. 2014 Feb 28;289(9):6142-51. doi: 10.1074/jbc.M113.517599. Epub 2014 Jan 13.

20.

Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection.

Christensen DP, Gysemans C, Lundh M, Dahllöf MS, Noesgaard D, Schmidt SF, Mandrup S, Birkbak N, Workman CT, Piemonti L, Blaabjerg L, Monzani V, Fossati G, Mascagni P, Paraskevas S, Aikin RA, Billestrup N, Grunnet LG, Dinarello CA, Mathieu C, Mandrup-Poulsen T.

Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1055-9. doi: 10.1073/pnas.1320850111. Epub 2014 Jan 6.

21.

Laparoscopic adrenalectomy for hemorrahagic adrenal pseudocyst discovered during pregnancy: report of a case.

Angelico R, Ciangola IC, Mascagni P, Manzia TM, Colizza S.

Surg Laparosc Endosc Percutan Tech. 2013 Oct;23(5):e200-4. doi: 10.1097/SLE.0b013e31828f6663.

PMID:
24105296
22.

Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat.

Consalvi S, Mozzetta C, Bettica P, Germani M, Fiorentini F, Del Bene F, Rocchetti M, Leoni F, Monzani V, Mascagni P, Puri PL, Saccone V.

Mol Med. 2013 May 20;19:79-87. doi: 10.2119/molmed.2013.00011.

23.

The lysine deacetylase inhibitor Givinostat inhibits β-cell IL-1β induced IL-1β transcription and processing.

Dahllöf MS, Christensen DP, Lundh M, Dinarello CA, Mascagni P, Grunnet LG, Mandrup-Poulsen T.

Islets. 2012 Nov-Dec;4(6):417-22. doi: 10.4161/isl.23541.

24.

[Metabolomic profiles of exhaled breath condensate of 39 nickel exposed workers].

Romano A, Aiani MR, Brambilla M, Brambilla P, Carcano M, Galbiati E, Porro S, Mascagni P.

G Ital Med Lav Ergon. 2012 Jul-Sep;34(3 Suppl):682-6. Italian.

PMID:
23405751
25.

[Chemical risk management in health care settings].

Crippa M, Bregante G, Carcano M, Mascagni P.

G Ital Med Lav Ergon. 2012 Jul-Sep;34(3 Suppl):252-6. Review. Italian.

PMID:
23405634
26.

Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients.

Amaru Calzada A, Pedrini O, Finazzi G, Leoni F, Mascagni P, Introna M, Rambaldi A, Golay J; Associazione Italiana per la Ricerca sul Cancro-Gruppo Italiano Malattie Mieloproliferative Investigators.

Exp Hematol. 2013 Mar;41(3):253-60.e2. doi: 10.1016/j.exphem.2012.10.013. Epub 2012 Oct 27.

PMID:
23111067
27.

Assessment of efficacy and safety of pandemic A/H1N1/2009 influenza vaccine in a group of health care workers.

Mascagni P, Vicenzi E, Kajaste-Rudnitski A, Pellicciotta G, Monti A, Cervi C, Vitalucci R, Toffoletto F.

Med Lav. 2012 May-Jun;103(3):220-9.

PMID:
22838300
28.

Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children.

Lundh M, Christensen DP, Damgaard Nielsen M, Richardson SJ, Dahllöf MS, Skovgaard T, Berthelsen J, Dinarello CA, Stevenazzi A, Mascagni P, Grunnet LG, Morgan NG, Mandrup-Poulsen T.

Diabetologia. 2012 Sep;55(9):2421-31. doi: 10.1007/s00125-012-2615-0. Epub 2012 Jul 7.

PMID:
22772764
29.

Functional consequences of inhibiting exocytosis of Weibel-Palade bodies in acute renal ischemia.

Yasuda K, Vasko R, Hayek P, Ratliff B, Bicer H, Mares J, Maruyama S, Bertuglia S, Mascagni P, Goligorsky MS.

Am J Physiol Renal Physiol. 2012 Mar 15;302(6):F713-21. doi: 10.1152/ajprenal.00541.2011. Epub 2011 Dec 7.

30.

Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer.

Dinarello CA, Fossati G, Mascagni P.

Mol Med. 2011 May-Jun;17(5-6):333-52. doi: 10.2119/molmed.2011.00116. Epub 2011 May 5.

31.

Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat).

Furlan A, Monzani V, Reznikov LL, Leoni F, Fossati G, Modena D, Mascagni P, Dinarello CA.

Mol Med. 2011 May-Jun;17(5-6):353-62. doi: 10.2119/molmed.2011.00020. Epub 2011 Feb 22.

32.

Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis.

Joosten LA, Leoni F, Meghji S, Mascagni P.

Mol Med. 2011 May-Jun;17(5-6):391-6. doi: 10.2119/molmed.2011.00058. Epub 2011 Feb 11.

33.

The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro.

Lewis EC, Blaabjerg L, Størling J, Ronn SG, Mascagni P, Dinarello CA, Mandrup-Poulsen T.

Mol Med. 2011 May-Jun;17(5-6):369-77. doi: 10.2119/molmed.2010.00152. Epub 2010 Dec 22.

34.

Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals.

Kajaste-Rudnitski A, Galli L, Nozza S, Tambussi G, Di Pietro A, Pellicciotta G, Monti A, Mascagni P, Moro M, Vicenzi E.

AIDS. 2011 Jan 14;25(2):177-83. doi: 10.1097/QAD.0b013e328341afa8.

PMID:
21150561
35.

Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines.

Lundh M, Christensen DP, Rasmussen DN, Mascagni P, Dinarello CA, Billestrup N, Grunnet LG, Mandrup-Poulsen T.

Diabetologia. 2010 Dec;53(12):2569-78. doi: 10.1007/s00125-010-1892-8. Epub 2010 Sep 28.

PMID:
20878317
36.

The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro.

Matalon S, Palmer BE, Nold MF, Furlan A, Kassu A, Fossati G, Mascagni P, Dinarello CA.

J Acquir Immune Defic Syndr. 2010 May 1;54(1):1-9. doi: 10.1097/QAI.0b013e3181d3dca3.

37.

Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury.

Shein NA, Grigoriadis N, Alexandrovich AG, Simeonidou C, Lourbopoulos A, Polyzoidou E, Trembovler V, Mascagni P, Dinarello CA, Shohami E.

FASEB J. 2009 Dec;23(12):4266-75. doi: 10.1096/fj.09-134700. Epub 2009 Sep 1.

38.

Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b.

Todoerti K, Barbui V, Pedrini O, Lionetti M, Fossati G, Mascagni P, Rambaldi A, Neri A, Introna M, Lombardi L, Golay J.

Haematologica. 2010 Feb;95(2):260-9. doi: 10.3324/haematol.2009.012088. Epub 2009 Aug 27.

39.

Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo.

Faraco G, Pittelli M, Cavone L, Fossati S, Porcu M, Mascagni P, Fossati G, Moroni F, Chiarugi A.

Neurobiol Dis. 2009 Nov;36(2):269-79. doi: 10.1016/j.nbd.2009.07.019. Epub 2009 Jul 25.

PMID:
19635561
40.

Cutting edge: Negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3.

Sun Y, Chin YE, Weisiger E, Malter C, Tawara I, Toubai T, Gatza E, Mascagni P, Dinarello CA, Reddy P.

J Immunol. 2009 May 15;182(10):5899-903. doi: 10.4049/jimmunol.0804388.

41.

Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice.

Reddy P, Sun Y, Toubai T, Duran-Struuck R, Clouthier SG, Weisiger E, Maeda Y, Tawara I, Krijanovski O, Gatza E, Liu C, Malter C, Mascagni P, Dinarello CA, Ferrara JL.

J Clin Invest. 2008 Jul;118(7):2562-73. doi: 10.1172/JCI34712.

42.

[Study of the olfactory function of a group of workers with significant lead exposure].

Caruso A, Lucchini R, Toffoletto F, Porro S, Moroni P, Mascagni P.

G Ital Med Lav Ergon. 2007 Jul-Sep;29(3 Suppl):460-3. Italian.

PMID:
18409777
43.

[Hearing function and solvent exposure: study of a worker population exposed to styrene].

Mascagni P, Formenti C, Pettazzoni M, Feltrin G, Toffoletto F.

G Ital Med Lav Ergon. 2007 Jul-Sep;29(3 Suppl):277-9. Italian.

PMID:
18409685
44.

[Health surveillance on workers exposed to wood dust: usefulness of the assessment of the nasal mucosa].

Porro S, Mascagni P, Ferraioli E, Toffoletto F.

G Ital Med Lav Ergon. 2007 Jul-Sep;29(3 Suppl):248-50. Italian.

PMID:
18409669
45.

Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice.

Glauben R, Batra A, Stroh T, Erben U, Fedke I, Lehr HA, Leoni F, Mascagni P, Dinarello CA, Zeitz M, Siegmund B.

Gut. 2008 May;57(5):613-22. doi: 10.1136/gut.2007.134650. Epub 2008 Jan 14.

PMID:
18194985
46.

ITF1697, a stable Lys-Pro-containing peptide, inhibits weibel-palade body exocytosis induced by ischemia/reperfusion and pressure elevation.

Bertuglia S, Ichimura H, Fossati G, Parthasarathi K, Leoni F, Modena D, Cremonesi P, Bhattacharya J, Mascagni P.

Mol Med. 2007 Nov-Dec;13(11-12):615-24.

47.

Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells.

Barbetti V, Gozzini A, Rovida E, Morandi A, Spinelli E, Fossati G, Mascagni P, Lübbert M, Dello Sbarba P, Santini V.

Oncogene. 2008 Mar 13;27(12):1767-78. Epub 2007 Sep 24.

PMID:
17891169
48.

The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.

Golay J, Cuppini L, Leoni F, Micò C, Barbui V, Domenghini M, Lombardi L, Neri A, Barbui AM, Salvi A, Pozzi P, Porro G, Pagani P, Fossati G, Mascagni P, Introna M, Rambaldi A.

Leukemia. 2007 Sep;21(9):1892-900. Epub 2007 Jul 19.

PMID:
17637810
49.

Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells.

Larsen L, Tonnesen M, Ronn SG, Størling J, Jørgensen S, Mascagni P, Dinarello CA, Billestrup N, Mandrup-Poulsen T.

Diabetologia. 2007 Apr;50(4):779-89. Epub 2007 Jan 31.

PMID:
17265033
50.

[The presence of asbestos bodies in induced sputum as an indicator of asbestos exposure].

Pettazzoni M, Rivolta G, Mascagni P, Carcano M, Porro S, Toffoletto F.

Med Lav. 2007 Jan-Feb;98(1):25-9. Italian.

PMID:
17240642

Supplemental Content

Loading ...
Support Center